A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Inclusion Criteria:

- adult patients, 18-75 years of age;

- type 2 diabetes receiving metformin and/or pioglitazone or rosiglitazone for at least
12 weeks;

- HbA1c >=7.0% and <=10% at screening;

- BMI >=25kg/m2 (>23kg/m2 for Asians) and <=45kg/m2 at screening;

- stable weight +/- 5% for at least 12 weeks prior to screening.

Exclusion Criteria:

- history of type 1 diabetes, diabetes resulting from pancreatic injury or secondary
forms of diabetes;

- history of acute metabolic diabetic complications within the previous 6 months;

- evidence of clinically significant diabetic complications;

- known proliferative diabetic retinopathy;

- myocardial infarction (MI), coronary artery bypass surgery, post-transplantation
cardiomyopathy (PTCM) or stroke within the past 6 months;

- any abnormality in clinical laboratory test or ECG, which precludes safe involvement
in the study as judged by the investigator;

- known hemoglobinopathy or chronic anemia;

- clinically significant gastrointestinal disease.